Compagnie Lombard Odier SCmA’s Ocular Therapeutix OCUL Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-700	Closed	-$6K	–	562
2020 Q2	$6K	Hold	700	–	–	﹤0.01%	495
2020 Q1	$3K	Hold	700	–	–	﹤0.01%	472
2019 Q4	$3K	Hold	700	–	–	﹤0.01%	491
2019 Q3	$2K	Hold	700	–	–	﹤0.01%	506
2019 Q2	$3K	Hold	700	–	–	﹤0.01%	494
2019 Q1	$3K	Hold	700	–	–	﹤0.01%	537
2018 Q4	$3K	Hold	700	–	–	﹤0.01%	524
2018 Q3	$5K	Hold	700	–	–	﹤0.01%	536
2018 Q2	$5K	Hold	700	–	–	﹤0.01%	572
2018 Q1	$5K	Sell	700 -700	-50%	-$3.94K	﹤0.01%	578
2017 Q4	$6K	Buy	1,400 +700	+100%	+$3.58K	﹤0.01%	617
2017 Q3	$4K	Hold	700	–	–	﹤0.01%	667
2017 Q2	$6K	Hold	700	–	–	﹤0.01%	668
2017 Q1	$6K	Sell	700 -1,500	-68%	-$12.5K	﹤0.01%	686
2016 Q4	$19K	Sell	2,200 -500	-19%	-$3.88K	﹤0.01%	706
2016 Q3	$19K	Buy	2,700 +2,000	+286%	+$12.2K	﹤0.01%	794
2016 Q2	$3K	Hold	700	–	–	﹤0.01%	875
2016 Q1	$7K	Hold	700	–	–	﹤0.01%	912
2015 Q4	$7K	Buy	+700	New	+$7.56K	﹤0.01%	879

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Compagnie Lombard Odier SCmA's OCUL Position: Q3 2020 in Review

Compagnie Lombard Odier SCmA sold out of Ocular Therapeutix (OCUL) in Q3 2020, closing a stake of 700 shares — an estimated $6K sold.

Compagnie Lombard Odier SCmA first reported a position in OCUL in Q4 2015 and held it in 19 quarters. The position peaked at $19K in Q4 2016. 108 funds tracked by Wall St. Rank hold OCUL as of Q3 2020.

Compagnie Lombard Odier SCmA reported no remaining Ocular Therapeutix position as of Q3 2020 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 700 Ocular Therapeutix shares in Q3 2020, an estimated $6K.
Compagnie Lombard Odier SCmA first reported a position in Ocular Therapeutix in Q4 2015 and held it in 19 quarters.
Compagnie Lombard Odier SCmA's Ocular Therapeutix position peaked at $19K in Q4 2016.
108 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2020.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2020, filed 12 Nov 2020.